Publication | Open Access

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

VaccinationVaccine SafetyVaccinologyTwo-dose Heterologous Ad26.zebovVaccine SurveillanceImmunologyVaccine TrialImmunodominanceVaccine TestingVaccine EfficacyMedicine